Evidence map›Paper›PMID 42861738›Full record

ArticleHematological oncology2026

The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL.

Michal Masar, Joseph P Novak, Janek S Walker, Prokop Vodicka, Abigail R Dropik, Zilin Xianyu, Matthew J Maurer, Thomas M Habermann, Eric Mou, Rebecca L King and 9 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Michal MasarFirst Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.ORCID https://orcid.org/0009-0007-0456-8030
Joseph P NovakDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Janek S WalkerDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-2049-1527
Prokop VodickaFirst Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.ORCID https://orcid.org/0000-0002-7848-1268
Abigail R DropikDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7543-5768
Zilin XianyuDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0009-0002-4216-0646
Matthew J MaurerDepartment of Quantitative Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-1867-0526
Thomas M HabermannDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-3532-9132
Eric MouDivision of Hematology, Oncology, Blood, and Marrow Transplantation, The University of Iowa, Iowa City, Iowa, USA.ORCID https://orcid.org/0000-0002-9865-4517
Rebecca L KingDivision of Hematopathology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Kerstin WenzlInformatics and Predictive Sciences, Bristol Myers Squibb, Summit, New Jersey, USA.
Thomas E WitzigDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-4215-6500
Stephen M AnsellDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-1244-6758
Pavel KlenerFirst Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.ORCID https://orcid.org/0000-0001-7786-9378
James R CerhanDepartment of Quantitative Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7482-178X
Marek TrnenyFirst Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.ORCID https://orcid.org/0000-0002-6952-6073
Yucai WangDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-1576-8341
Magdalena KlanovaFirst Department of Medicine, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
Anne J NovakDivision of Hematology, Mayo Clinic Rochester, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7904-1651

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
Genetic Predictors of Early Clinical Failure in Diffuse Large B Cell LymphomaR01CA212162 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, NOVAK, ANNE JOSEPHINE · 2017 to 2021
$3.3M
Ministerstvo Zdravotnictví Ceské Republiky NU23-03-00127NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA212162NCI NIH HHS U01 CA195568NIH HHS R01 CA212162-01A1NIH HHS SPORE-P50 CA97274NIH HHS U01 CA195568Predolin Foundation BiobankTanoto Foundation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

b celldiffuse large b‐cell lymphomagenomicslarge‐cell lymphomalate relapsemedicineoncologyrelapsed lymphomatranscriptome profiling

Identifiers

PMID42861738
PMCPMC13656328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.